Hengmiao Cheng
The University of Sydney(AU)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Chemical Synthesis and Analysis, Inflammatory mediators and NSAID effects, Synthesis and biological activity
Most-Cited Works
- → PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity(2011)159 cited
- → Recent progress on third generation covalent EGFR inhibitors(2016)106 cited
- → Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer(2012)103 cited
- → Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants(2016)93 cited
- → Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR(2017)89 cited
- → Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design(2012)79 cited
- → Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design(2010)73 cited
- → Formation of peptide amides by peptidylglycine .alpha.-amidating monooxygenase: a new assay and stereochemistry of hydrogen loss(1988)55 cited
- → 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure–activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog(2005)51 cited
- → Synthesis and Activity of a Novel Class of Tribasic Macrocyclic Antibiotics: The Triamilides(2002)45 cited